Items Tagged ‘xilonix’

August 24th, 2015

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing

By

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at multiple sites. Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established […]

View full entry

Tags: advanced colorectal cancer, clinical trail, Colon Cancer, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xilonix


May 20th, 2015

Xilonix™ Promising as Treatment for Non–Small Cell Lung Cancer

By

The new targeted agent Xilonix™ appears effective in the treatment a non–small cell lung cancer (NSCLC). The biotechnology company XBoitech Inc recently announced clinical trial findings for the drug.[i],[ii] Xilonix is a type of drug known as a true human antibody. These types of drugs use antibodies that are made in the lab rather than […]

View full entry

Tags: antibody therapy, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, true human antibody, xilonix


February 19th, 2015

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer

By

The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According to estimates from the American Cancer Society, 93,090 cases of colon cancer and 39,610 cases of rectal cancer will be diagnosed in 2015. Colorectal […]

View full entry

Tags: advanced colorectal cancer, clinical trial, Colon Cancer, colon cancer treatment, colorectal cancer, crc, interleukin, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer